Katherine E Tierney1, Lingyun Ji2, Shannon S Dralla1, Eunjeong Yoo3, Annie Yessaian1, Huyen Q Pham1, Lynda Roman1, Richard Sposto2, Paulette Mhawech-Fauceglia4, Yvonne G Lin5. 1. Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, University of Southern California, Los Angeles, CA, United States. 2. Biostatistics Shared Resource, USC Norris Comprehensive Cancer Center, and Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. 3. Women's Cancer Program, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States. 4. Department of Pathology and Gynecologic Oncology, University of Southern California, Los Angeles, CA, United States. Electronic address: pfauceglia@hotmail.com. 5. Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, University of Southern California, Los Angeles, CA, United States; Women's Cancer Program, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States.
Abstract
Glucose-regulated protein (GRP)-78, the key regulator of endoplasmic reticulum (ER) stress, is associated with endometrial cancer (EC) development and progression. However, its role in the continuum from complex atypical hyperplasia (CAH) to EC is unknown and the focus of this study. METHODS: 252 formalin-fixed, paraffin-embedded endometrial biopsies from patients with CAH diagnosed between 2003 and 2011 were evaluated for GRP78 expression by immunohistochemistry. Expression was also evaluated in subsequent biopsies from those patients treated with progestins. Differences in GRP78 expression were assessed using standard statistical methods. RESULTS: GRP78 expression was undetectable in 45(18%) patients with CAH, while 120(48%) CAH cases showed moderate/strong expression. Among women who ultimately underwent hysterectomy for CAH (n=134), 54(40%) had occult EC while 57(43%) had persistent CAH. Those with occult EC upon hysterectomy had significantly stronger GRP78 expression than those who did not have occult EC (p=0.007). Greater GRP78 expression within CAH remained independently associated with the presence of an occult EC (p=0.017). Thirty-four of 54 (63%) patients with occult EC had moderate/strong GRP78 expression compared to 36 of 80 (45%) patients with persistent CAH, benign or non-atypical hyperplastic endometrium. In those treated with progestins, samples with persistent CAH and EC were more likely to have high levels of GRP78 expression in the initial biopsies than those who responded (p=0.014). CONCLUSIONS: Increased GRP78 expression in untreated CAH correlates with the presence of an occult EC. In addition, CAH specimens with greater GRP78 expression may identify patients who are less likely to respond to progestin therapy.
Glucose-regulated protein (GRP)-78, the key regulator of endoplasmic reticulum (ER) stress, is associated with endometrial cancer (EC) development and progression. However, its role in the continuum from complex atypical hyperplasia (CAH) to EC is unknown and the focus of this study. METHODS: 252 formalin-fixed, paraffin-embedded endometrial biopsies from patients with CAH diagnosed between 2003 and 2011 were evaluated for GRP78 expression by immunohistochemistry. Expression was also evaluated in subsequent biopsies from those patients treated with progestins. Differences in GRP78 expression were assessed using standard statistical methods. RESULTS:GRP78 expression was undetectable in 45(18%) patients with CAH, while 120(48%) CAH cases showed moderate/strong expression. Among women who ultimately underwent hysterectomy for CAH (n=134), 54(40%) had occult EC while 57(43%) had persistent CAH. Those with occult EC upon hysterectomy had significantly stronger GRP78 expression than those who did not have occult EC (p=0.007). Greater GRP78 expression within CAH remained independently associated with the presence of an occult EC (p=0.017). Thirty-four of 54 (63%) patients with occult EC had moderate/strong GRP78 expression compared to 36 of 80 (45%) patients with persistent CAH, benign or non-atypical hyperplastic endometrium. In those treated with progestins, samples with persistent CAH and EC were more likely to have high levels of GRP78 expression in the initial biopsies than those who responded (p=0.014). CONCLUSIONS: Increased GRP78 expression in untreated CAH correlates with the presence of an occult EC. In addition, CAH specimens with greater GRP78 expression may identify patients who are less likely to respond to progestin therapy.
Authors: Giuseppe Bifulco; Claudia Miele; Bruno Di Jeso; Francesco Beguinot; Carmine Nappi; Costantino Di Carlo; Silvana Capuozzo; Giuseppe Terrazzano; Luigi Insabato; Luca Ulianich Journal: Gynecol Oncol Date: 2011-12-04 Impact factor: 5.482
Authors: Richard J Zaino; James Kauderer; Cornelia Liu Trimble; Steven G Silverberg; John P Curtin; Peter C Lim; Donald G Gallup Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Mario M Leitao; Guangming Han; Lisa X Lee; Nadeem R Abu-Rustum; Carol L Brown; Dennis S Chi; Yukio Sonoda; Douglas A Levine; Ginger J Gardner; Elizabeth E Jewell; Richard R Barakat; Robert A Soslow Journal: Am J Obstet Gynecol Date: 2010-06-23 Impact factor: 8.661
Authors: Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Michael J Gray; Paulette Mhawech-Fauceglia; Eunjeong Yoo; Wangrong Yang; Eijean Wu; Amy S Lee; Yvonne G Lin Journal: Int J Cancer Date: 2013-02-08 Impact factor: 7.396
Authors: Rachel S Mandelbaum; Marcia A Ciccone; David J Nusbaum; Mahdi Khoshchehreh; Heena Purswani; Elise B Morocco; Meghan B Smith; Shinya Matsuzaki; Christina E Dancz; Begum Ozel; Lynda D Roman; Richard J Paulson; Koji Matsuo Journal: Am J Obstet Gynecol Date: 2020-01-21 Impact factor: 8.661
Authors: Michelle T Doherty; Omolara B Sanni; Helen G Coleman; Chris R Cardwell; W Glenn McCluggage; Declan Quinn; James Wylie; Úna C McMenamin Journal: PLoS One Date: 2020-04-28 Impact factor: 3.240